MedTrace Logo

Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

NCT03688035 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-09-27

No results posted yet for this study

Summary

Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the circulating free DNA in the blood that originates from cancers,and it can be detected by modern technologies in plasma.In this prospective study,investigators aim to observe the correlation between tumor response to neoadjuvant chemotherapy and ctDNA.

Conditions

Sponsors & Collaborators

  • Zhiyong Yu

    lead OTHER

Principal Investigators

  • Zhiyong Yu, PHD · Shandong Cancer Hospital and Institute

  • Zhaoyun Liu, MD · Shandong Cancer Hospital and Institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-20
Primary Completion
2019-09-20
Completion
2019-09-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688035 on ClinicalTrials.gov